Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Navacaprant (BTRX-335140) | KOR Antagonist | MedChemExpress
navacaprant | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Neumora Therapeutics (NMRA): ¿Llegarán noticias sobre Navacaprant (NMRA ...
navacaprant (NMRA-140) - News, Articles etc. - European Pharmaceutical ...
Neumora Therapeutics Reports Positive Navacaprant Data in MDD
navacaprant (NMRA-140) / Neumora Therap
Navacaprant for Major Depressive Disorder Fails in Late-Stage Study
Neumora's Depression Drug Navacaprant Fails Primary Endpoint in Pivotal ...
Navacaprant - Drug Targets, Indications, Patents - Synapse
Navacaprant for Major Depressive Disorder Fails in Late-Stage Study ...
Neumora's Navacaprant Fails Phase 3, Shares Plunge | VT News
Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA ...
Neumora Therapeutics' depression drug fails to meet main goal of late ...
Neumora大跌81%：Navacaprant重度抑郁三期临床失败 Armstrong 2025年1月2日，Neumora ...
AI analyzes Neumora Therapeutics (NMRA)
有效恢复快感！创新药物3期关键试验即将启动，治疗重度抑郁 Neumora Therapeutics 今天宣布，计划启动KOASTAL项目，这是 ...
Neumora Therapeutics Announces Initiation of Phase 2 Study of ...
Major depressive disorder therapy to enter Phase 3 pivotal clinical ...
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program ...
El nuevo fármaco de Neumora contra la depresión no cumple las ...
Navacaprant(Navacaprant) - 药物靶点：κ opioid receptor_在研适应症：重度抑郁症，抑郁症，躁郁症2型 ...
Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In ...
III期临床阶段生物科技公司：Neumora Therapeutics Inc.(NMRA) | 美股之家 - 港股美股开户投资百科全书
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back ...
Neumora Therapeutics, Inc. Common Stock Stock Report — NMRA — Roic AI
Depression-focused Neumora Therapeutics plots late-stage drug trials ...
Neumora Therapeutics Spearheads New Phase in Bipolar Depression and ...
Neumora Therapeutics: A 2026 Catalyst Play in Neuroscience Innovation
BCBN Feed: Neumora Therapeutics Announces Initiation of Phase 3 ...
Neumora Therapeutics, Inc. (NMRA) Stock Price, Quote & News
Neumora Therapeutics Antidepressant Stumbles in Clinical Trial – ISPE ...
Neumora Therapeutics logo in transparent PNG and vectorized SVG formats
Neumora Therapeutics (NMRA): A Biopharma Undervalued Amid Strategic ...
Neumora Therapeutics | 🦈ลงทุนแบบปอปลา🐳 (@popla3634)
10-K
Neumora Reveals Mid-Stage Data For Fully Funded, Phase III-Ready ...
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor ...
Neumora Therapeutics, Inc. (NMRA) Stock Price, News, Quote & History ...
Neumora Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Neumora: First Novel Mechanism Of Action Drug In Major Depression In ...
Neumora Therapeutics (NASDAQ:NMRA) Upgraded by Guggenheim to "Buy" Rating
(Navacaprant) - 药物靶点：κ opioid receptor_在研适应症：重度抑郁症，躁郁症_专利_临床_研发
Startup Neumora takes a novel depression drug to Phase 3
美 FDA, 뉴모라의 조현병 치료제 ‘NMRA-266’ 임상 1상 시험 보류 명령 - 바이오타임즈
Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core ...
Neumora’s antidepressant stumbles in first Phase 3 trial readout
Bioactive Small Molecules|Pharmaceutical Intermediates|Heterocyclic ...
Neumora’s Kappa Opioid Antagonist Falters in Phase 3 Depression Trial
Ligand-specific interactions with KOR a, The binding poses of momSalB ...
Navacaprant: A Hot Topic at the ACNP 2023 Annual Meeting
Norepinephrine Reuptake Inhibitor
Navacaprant, a Novel Kappa Opioid Receptor Antagonist for Major ...
Neumora's Depression Drug Trial Failure: A $2 Billion Blow to Biotech ...
Stock in Biotech Neumora Plunges 80% as Depression Drug Fails - Barron's
Neumora Therapeutics Shares Plummet After Depression Drug Trial Failure ...
Neumora精神分裂症药物试验被FDA暂停，将专注于开发其他管线_摩熵医药(原药融云)
An Arch-backed biotech pushes its depression drug into late-stage ...
Neumora Shakes Up Phase III MDD Trials After January Miss - BioSpace
2025年，BioTech的首个股价暴跌出现！跌幅超过80% 当地时间2025年1月2日，Neumora Therapeutics ...
뉴모라, KOR 길항제 '나바카프란트' MDD 임상3상 실패…주가 81% 급락
Neumora Therapeutics (NASDAQ:NMRA) Stock Price Expected to Rise, Mizuho ...
Neumora shares slide as J&J’s drug failure raises doubts about ...
Frontiers | CTNNB1 in neurodevelopmental disorders
Neumora’s Novel Depression Drug Strikes Out in First Pivotal Trial ...
navacaprant-药品详情-NextPharma®数据库-ByDrug-医药魔方数据库
Just back from an energizing trip with our Neumora clinical team to ...
The Psychiatric Pipeline in Review: Quarter 1, 2025
Neumora Plunges After Depression Drug Fails in Final-Stage Study
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating
Comparison of cryo-EM structure of alvimopan-bound MOR with crystal ...
1-(6-Ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2 ...
우울증 치료제 ′나바카프란트′ 후기 임상시험 실패...뉴모라 주식 80% 이상 하락
Kuehn Law Investigates Neumora Therapeutics Shareholder Concerns: A ...
Pathophysiology of depression and mechanisms of treatment. - Abstract ...
2025年，BioTech的首个股价暴跌出现！跌幅超过80% - 药时代DrugTimes
CNS领域新型整合型 Biotech 美股IPO在即，网页链接。 Neumora ，跑的最快的是navacaprant（... - 雪球
#newbeginnings #neumora #neuropsychiatry #neuroscience | Pharmaceutical ...
Oral monotherapy for major depressive disorder entering phase 3 trials
BioCentury - Head of R&D Robert Lenz to leave Neumora
最新盘点！2022年FDA批准上市的小分子化学创新药及合成路线 - 知乎
Modification and optimization of NRAP antibiotics. (A) The peripheral ...
聚焦抑郁症精准疗法开发！新锐完成1.12亿美元B轮融资 Neumora Therapeutics 今日宣布完成1.12亿美元B轮融资。这是继约 ...
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In ...
:max_bytes(150000):strip_icc()/NMRA_2025-01-02_10-09-15-0f80ba3f0dc541b29540f601e1a20f4a.png)
_2244614-14-8.png)
